Sign in
CompletedPhase 1/2

Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury

Key facts

Who runs it
University of Minnesota
Where
Englewood and Minneapolis, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
24 people enrolled
Started
1 Feb 2021
Ended
1 Sept 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Brivaracetam
  • Placebo
Record updated
14 October 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Spinal cord injury (SCI)
  • Participants must have completed inpatient rehabilitation and are living in the community
  • Participant who have severe below-level neuropathic pain (daily average 9/10 or 10/10)
  • Participants must have tried and failed to achieve adequate pain relief with the use of other drugs (i.e treatment failed to decrease their pain below a level of 9) and can continue to take spasmolytics, pregabalin, gabapentin, and opioids in unchanged dosing throughout the trial

Who cannot take part

  • Epilepsy
  • Contraindications to brivaracetam or pyrrolidine derivatives including allergy, or contraindications to MRI including retained bullet fragments, noncompatible metal implants, and implanted devices such as baclofen pumps
  • Pprogressive myelopathy secondary to posttraumatic cord tethering
  • Syringomyelia
  • Brain injury limiting the ability to follow directions
  • Pregnancy or lactation
  • Impaired liver or renal function

Where in United States

  • Swedish HospitalEnglewood, United States
  • University of Minnesota School of MedicineMinneapolis, United States

About the trial

What the trial wants to find out

Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to all pharmacological intervention. Preliminary data suggest brivarecetum is a mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized, placebo-controlled pilot clinical trial will assess feasibility of a 3-month treatment course with brivarecetum.

The 2 groups in the trial

  • Brivaracetam GroupTreatment being tested

    Participants in this arm will receive the investigational drug, Brivaracetam.

    Treatment: Brivaracetam

  • Control GroupPlacebo, for comparison

    Participants in this arm will receive a placebo.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Pilot Clinical Trial
Record updated
14 October 2025